Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06039605 · ClinicalTrials.gov registry record · NA

Priming Expectations and Motor Learning With tDCS

A NA study, sponsored by Arizona State University.

Completed
Registry status
NA
Development phase
140
Enrollment target

NCT06039605: Completed NA study, sponsored by Arizona State University.

NCT06039605 is a NA study that has completed, run by Arizona State University. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06039605, a NA study, has completed, sponsored by Arizona State University.

COMPLETED
Registry status
NA
Development phase
140 participants
Enrollment target

Study Summary

The purpose of this study is to test if priming expectations of transcranial Direct Current Stimulation (tDCS) can improve the efficacy of tDCS in enhancing motor learning.

Primary Outcome

This will be calculated as the average of two trials of the motor task that are completed one week after the last training session. The motor task is a timed test that requires participants to spoon two beans (kidney, raw) at a time from a center proximal "start" cup to three distal "target" cups as fast as possible. In short, this task requires multijoint coordination and limb reversal, and performance for each trial is measured in seconds.

Interventions

  • DEVICE Transcranial Direct Current Stimulation

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-10-23
Est. Completion 2025-04-16
Phase NA
Arizona State University

187 total trials

What the finished NCT06039605 record still lists

NCT06039605 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which Transcranial Direct Current Stimulation is the first listed.

NCT06039605 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06039605 about?

NCT06039605 is a clinical study titled "Priming Expectations and Motor Learning With tDCS". The purpose of this study is to test if priming expectations of transcranial Direct Current Stimulation (tDCS) can improve the efficacy of tDCS in enhancing motor learning.

What is the current status of trial NCT06039605?

This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2023-10-23. Estimated completion is 2025-04-16.

What interventions are being tested in trial NCT06039605?

The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06039605?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06039605's enrollment target sits among peer trials

140 713th of 2000 higher than 1,281 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06039605, the US trial registry maintained by the National Library of Medicine. NCT06039605 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.